We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia?
- Authors
Molica, Stefano; Digiesi, Giovanna; Vacca, Angelo; Mirabelli, Rosanna; Todoerti, Katia; Battaglia, Caterina; Morabito, Fortunato; Neri, Antonino; Ribatti, Domenico
- Abstract
Angiogenesis is involved in the pathogenesis of B-cell chronic lymphocytic leukemia (CLL), and high microvascular density has been found in CLL to be associated with a poor prognosis. In this study, we assessed serum levels of adiponectin in 69 patients with Binet stage A B-CLL, and these values were retrospectively correlated with bone marrow (BM) microvessel area and serum levels of vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), angiogenin, PECAM-1 (CD31), matrix metalloproteinase-9 (MMP-9), interleukin-8 (IL-8), syndecan-1, and the percentage of CD38+ or ZAP-70+ CLL cells. The positive correlation between serum levels of adiponectin and VEGF (P = .03) does not translate into an increase of the extent of BM angiogenesis (P = .404), FGF-2 (P = .348), angiogenin (P = .402), and CD31 (P = .248) serum concentrations. Accordingly, IL-8 (P = .175), syndecan-1 (P = .06), and MMP-9 (P = .144) circulating levels were not likely to reflect adiponectin concentration. Furthermore, patients with higher levels of adiponectin had a more favorable biological profile as defined by a lower number of both CD38- (r = -0.294; P = .02) and ZAP-70+ (r = -0.285; P = .04). Finally, we evaluated the presence of adiponectin in B-CLL cells at gene expression level. RMA intensity values for adiponectin gene transcript denote a homogeneous low expression in B-CLL cells, whereas VEGF transcript was highly expressed with a degree of interpatient variability. Overall, these data seem to indicate that adiponectin could be involved as an antiangiogenic factor in B-CLL.
- Subjects
LYMPHOCYTIC leukemia; B cells; NEOVASCULARIZATION; BONE marrow diseases; CANCER prognosis; IMMUNE system; GENE expression; PEPTIDES; METALLOPROTEINASES; GENETICS; DISEASES
- Publication
Advances in Hematology, 2009, Vol 2009, p1
- ISSN
1687-9104
- Publication type
Article
- DOI
10.1155/2009/287974